A new study examines how a diabetes drug may protect the kidneys from aging.
Designed to reinforce lucerastat as the first oral therapy suitable for all patients with Fabry disease, irrespective of their mutation type. The program is expected to support a potential regulatory ...
Allschwil, Switzerland - February 06, 2026Idorsia Ltd (SIX: IDIA) announces the design of its FDA-agreed Phase 3 registration program for lucerastat in Fabry disease. Building on the robust biomarker ...
BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...
Ketosis is a natural metabolic state that is generally safe, but some aspects of it may be dangerous. Popularized by the keto diet, ketosis comes with the risk of several side effects, some of which ...